Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;7(6):481-483.
doi: 10.21037/hbsn.2018.11.12.

The role of gut microbiota in immune checkpoint inhibitor therapy

Ming Yi  1 , Shuang Qin  1 , Qian Chu  1 , Kongming Wu  1
Affiliations
Editorial

The role of gut microbiota in immune checkpoint inhibitor therapy

Ming Yi et al. Hepatobiliary Surg Nutr. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Main mechanism by which the gut microbiota influences ICI treatment. The homology between non-self material of the gut microbiota and tumor antigen induces cross-reactivity of T cells. Dendritic cells (DC) recognize the non-self material of gut microbiota, then present the antigen and activate the T cells in the lymph node. Exposure to antigens and central memory T cells (TCM) is formed. Subsequently, accumulated TCM in tumor bed could differentiate to effector T cell and further recruit effector T cells from peripheral circulation. The increased T cell activity has a positive influence on immune checkpoint inhibitor (ICI) treatment.
See this image and copyright information in PMC

Comment on

  • Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
    Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494

References

    1. Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 2018;15:671-82. 10.1038/s41575-018-0025-6 - DOI - PubMed
    1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541:321-30. 10.1038/nature21349 - DOI - PubMed
    1. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7. 10.1126/science.aan3706 - DOI - PubMed
    1. Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol 2018;11:31. 10.1186/s13045-018-0578-4 - DOI - PMC - PubMed
    1. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9. 10.1126/science.aac4255 - DOI - PMC - PubMed